Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.30)
# 3,039
Out of 4,479 analysts
31
Total ratings
12%
Success rate
-27.56%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $22.15 | +193.45% | 7 | Jun 24, 2024 | |
| LEGN Legend Biotech | Initiates: Overweight | $82 | $44.74 | +83.28% | 1 | Apr 3, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $1.60 | - | 1 | Nov 8, 2023 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $56 → $32 | $22.57 | +41.78% | 9 | Oct 17, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $22 | $5.00 | +340.00% | 3 | Sep 13, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $4.54 | +208.37% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $53.12 | +101.45% | 4 | Aug 8, 2022 |
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $22.15
Upside: +193.45%
Legend Biotech
Apr 3, 2024
Initiates: Overweight
Price Target: $82
Current: $44.74
Upside: +83.28%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.60
Upside: -
Beam Therapeutics
Oct 17, 2023
Maintains: Overweight
Price Target: $56 → $32
Current: $22.57
Upside: +41.78%
Verve Therapeutics
Sep 13, 2023
Reiterates: Neutral
Price Target: $22
Current: $5.00
Upside: +340.00%
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $4.54
Upside: +208.37%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $53.12
Upside: +101.45%